Article Information
PubMed
History
- Published online May 22, 2006.
Article Versions
- Latest version (May 2, 2006 - 13:20).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2006 CMA Media Inc. or its licensors
Author Information
- Linda E. Lévesque,
- James M. Brophy,
- Bin Zhang
- From the Department of Epidemiology and Biostatistics (Lévesque, Brophy, Zhang) and the Department of Medicine, McGill University Health Centre (Brophy), McGill University, Montréal, Que., and the Department of Community Health and Epidemiology, Queen's University, and Kingston, Frontenac, Lennox and Addington Public Health, Kingston, Ont. (Lévesque)
- Correspondence to:
Dr. James Brophy, Divisions of Cardiology and Clinical Epidemiology, CHUM/MUHC Technology Assessment Unit (Director), Royal Victoria Hospital, 687 Pine Ave. W., Ross 4.12, Montréal QC H3A 1A1; fax 514 843-1493; james.brophy{at}mcgill.ca
Statistics from Altmetric.com
Cited By...
In this issue
Article tools
Respond to this article
Jump to section
Related Articles
Cited By...
- COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
- Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study
- Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes
- Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding
- Cardiac risks with COX-2 inhibitors
- Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
- Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
- Balancing the cyclooxygenase portfolio.
More in this TOC Section
Similar Articles
